The Image Of Drug Discovery

About Ekam Imaging

Since its establishment in 2008, Ekam Imaging has emerged as the undisputed leader in preclinical Magnetic Resonance Imaging. As the only Contract Research Organization (CRO) that conducts MRI scans on conscious and awake subjects, our approach guarantees results that are highly predictive of clinical outcomes. By leveraging the best possible method for ensuring accurate and relevant data, Ekam Imaging is at the forefront of preclinical research, providing our clients with unparalleled insights and expertise.

Located in Boston, Ekam Imaging is a hybrid CRO that partners with MR Imaging centers in top universities in the area, this strategic partnership allows us to utilize cutting-edge instrumentation and a highly skilled workforce, enabling us to consistently deliver reliable and high-quality results in a timely manner. At Ekam, our team is led by top scientists in the field, ensuring that our services are conducted to the highest standards of scientific rigor. With our state-of-the-art facilities, experienced staff, and commitment to excellence, Ekam Imaging is the ideal partner for preclinical Magnetic Resonance Imaging research.

Our Services

Awake Animal Imaging

While anesthetics are commonly used to reduce motion in MRI studies, they can have notable effects on the central nervous, cardiovascular, and respiratory systems.

Behavioral Assays

Assessing neurological traits and events in rodents is an essential part of neurological research, and behavioral testing plays a vital role in evaluating these factors.

MRI Brain Atlases

Ekam has developed its own MRI based 3D animal brain atlases, which segment the brain into distinct areas for use in registration, and data analysis.

Animal Models for Human Disorders

Animal models of human disorders are used in research to understand the biological mechanisms that underlie these disorders and to develop new treatments. While it is not always ……..

MRI Coils

Awake animal imaging has revolutionized preclinical research in neuroscience, allowing researchers to capture more accurate and clinically relevant data by eliminating the

Neurotoxicity

Approximately one quarter of small molecules in drug development intended for CNS indications fail in clinical trials due to neurotoxicity issues, which are often not identified during drug discovery stages.